Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Non Operating Income: 2015-2025

Historic Other Non Operating Income for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $40.3 million.

  • Spyre Therapeutics' Other Non Operating Income rose 314.48% to $40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 199.64%. This contributed to the annual value of -$20.7 million for FY2024, which is 8.27% down from last year.
  • Per Spyre Therapeutics' latest filing, its Other Non Operating Income stood at $40.3 million for Q3 2025, which was up 6,247.26% from -$656,000 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Other Non Operating Income ranged from a high of $40.3 million in Q3 2025 and a low of -$21.4 million during Q4 2023.
  • Moreover, its 3-year median value for Other Non Operating Income was -$483,000 (2024), whereas its average is $192,091.
  • Within the past 5 years, the most significant YoY rise in Spyre Therapeutics' Other Non Operating Income was 9,658.33% (2023), while the steepest drop was 66,750.00% (2023).
  • Over the past 5 years, Spyre Therapeutics' Other Non Operating Income (Quarterly) stood at -$15,000 in 2021, then slumped by 113.33% to -$32,000 in 2022, then plummeted by 66,750.00% to -$21.4 million in 2023, then skyrocketed by 96.18% to -$818,000 in 2024, then surged by 314.48% to $40.3 million in 2025.
  • Its last three reported values are $40.3 million in Q3 2025, -$656,000 for Q2 2025, and $2.3 million during Q1 2025.